Actinium Pharmaceuticals (NYSE:ATNM) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a report published on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.52 on Wednesday. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24. The stock has a market capitalization of $47.42 million, a P/E ratio of -1.09 and a beta of 0.10. The business’s 50-day simple moving average is $1.27 and its 200-day simple moving average is $1.44.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vontobel Holding Ltd. acquired a new stake in shares of Actinium Pharmaceuticals during the fourth quarter worth $32,000. Sei Investments Co. purchased a new position in Actinium Pharmaceuticals during the 4th quarter worth $62,000. Barclays PLC lifted its stake in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the period. Bank of America Corp DE lifted its stake in shares of Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after acquiring an additional 34,176 shares during the period. Finally, Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth about $112,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).